The Minister of Industry and Mineral Resources of the Kingdom of Saudi Arabia, Bandar Alkhorayef, has inaugurated the advanced pharmaceuticals factory Bpharma in Jeddah, marking a major milestone in the Kingdom’s growing pharmaceutical sector.
The Bpharma project represents a major national initiative with an initial investment exceeding $120 million (SAR 450 million), which is expected to surpass $174 million (SAR 650 million) upon completion of its second phase, reflecting strong investor confidence and sustained growth potential in Saudi Arabia’s pharmaceutical sector.
The project supports national efforts to localize drug manufacturing, strengthen supply chain efficiency, and enhance long-term health security across the Kingdom.
The Bpharma factory spans approximately 38,000 square meters and adheres to the highest engineering and operational standards, incorporating full automation and advanced technologies to ensure high production efficiency, enhanced operational reliability, strict quality control compliance, and consistent output in line with international pharmaceutical regulations.
This advanced pharmaceuticals factory features advanced production lines for sterile products, initially capable of producing 250 million units annually, with output expected to increase to over 450 million units in the second phase. Its product range includes critical care items, specialized medicines, as well as ophthalmic and respiratory products, catering to diverse healthcare needs across the Kingdom.
The Bpharma project is projected to create 250 jobs in the first phase and approximately 600 jobs upon completion of the second phase, with a strong emphasis on developing national talent through specialized training programs and skill-building initiatives.
This advanced pharmaceuticals factory directly supports Saudi Vision 2030’s objectives of localizing the pharmaceutical industry, strengthening domestic healthcare capabilities, and enhancing national health security.
